No abstract

The account of dependence of moisture conductivity coefficient, thermal conductivity coefficient and heat capacity on temperature and moisture is the main peculiarity of the new physico-mathematical model of combined heat and moisture transfer in walls of low-rise wooden insulated timber buildings. This study is aimed at refining and testing such model, including preliminary evaluation of influence of moisture transfer processes on moisture accumulation in insulated timber structures with connectors at low outside temperatures. The study provides approximation dependences that illustrate variation in thermal characteristics of wooden structures made of timber, plywood and insulation. The results of numerical simulation of heat and mass transfer processes occurring in a representative wall fragment made of high-strength profiled timber are given. Temperature and moisture fields are calculated in a selected inhomogeneous fragment. Maximum humidification in insulated profiled timber walls is located on the external surface of the wall. It is found that the use of additional internal longitudinal lamellae in timber with vertical connectors leads to significantly uneven moisture distribution. Based on the calculation results one may conclude that the wall fragment under study has no areas where free moisture can be possibly accumulated.

No abstract

No abstract

Iron deficiency is one of the leading factors in the global burden of disease, affecting mainly children, premenopausal women and low- and middle-income people. With prolonged iron deficiency, iron deficiency anemia (IDA) develops, which, according to the World Health Organization (WHO), remains the most common type of anemia worldwide. The most common causes of IDA include gastrointestinal bleeding, menstrual blood loss and pregnancy in women. Currently, divalent iron preparations are considered the “gold standard” of IDA therapy. To date, there are preparations of divalent iron with delayed release. The advantage of this form is that such drugs are better tolerated, they have a lower incidence of side effects with comparable bioavailability and efficacy compared to conventional forms. Such drugs include Tardyferon®.In our study, it was noted that against the  background of  taking Tardyferon®, the level of ferritin by the end of the 1st month of therapy in patients with latent iron deficiency increased from 12.4 ± 0.93 to 27.8  ± 4.1 µg/L (p ≤ 0.05). In patients with IDA, it increased from 9.7 ± 1.3 to 25.4 = 5.1 µg/L. By the end of the 3rd month of treatment, the ferritin level in patients with latent iron deficiency was 200.1 ± 30.8 (p < 0.05), and in patients with IDA – 246.7 µg/L (p < 0.05). We noted a similar dynamic in the hemoglobin level: in patients with IDA, it increased from 97.4 ± 9.3 g/L to 125.8 ± 10.2 g/l (p < 0.05), and in 21 (75%) of 28 patients it reached normal values (more than 120 g/L) by the end of the 1st months of therapy.By the 3rd month of  therapy, all patients with IDA had already reached the  target level, and the  average hemoglobin value in  the group was 142.1 ± 5.6 g/L (p = 0.05).Thus, in patients with IDA, against the background of therapy with Tardyferon®, hemogram indicators normalize, the concentration of hemoglobin and ferritin increases by the end of the 1st month of therapy.